The 2020 Retinal Pharmaceuticals Market Report features new estimates that incorporate the impact of COVID-19 in 2020, an updated disease model based on disease prevalence by ethnicity, and updated estimations of severe NPDR. The report now discusses Beovu, biosimilars and relevant marketing agreements, gene therapy delivery methods and instruments, orally administered drug candidates in development, and eye drop retinal drug delivery. The 2020 report covers more development-stage programs, gene therapies, anti-inflammatories, sustained drug-delivery devices, and market competitors.
A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.